The Quest for a Universal Influenza Vaccine: Within reach or beyond our grasp?

[Available On-Demand] ・ Click video to start playback;Join chat Q&A below video
Search General Info
For more than a decade governments, thought leaders and industry have called for but questioned the feasibility of a “universal flu” vaccine. Researchers and vaccine innovators have pursued novel development technologies seeking transformational solutions in parallel with incremental improvements to existing influenza vaccines. Grand Challenges and funding for vaccine innovation centers have encouraged interdisciplinary collaboration and cross-fertilization of ideas from outside the traditional influenza research community.
The response to COVID-19 has identified >100 vaccine candidates in less than five months and inspired “unprecedented global collaboration” to face this pandemic.
What will it take to move beyond incremental improvements in the performance of seasonal influenza vaccines and inspire a similar response from the research and development community in pursuit of game-changing vaccines to prevent seasonal and pandemic influenza?
This panel will discuss both the scientific possibility as well as the policy and commercial implications of a universal influenza vaccine. Participants will also help define what the term means and the iterative stages of innovation that we should anticipate over the next 5-10 years.
Moderator
photo
President, Global Immunization
Sabin Vaccine Institute
Speakers
photo
Chief Clinical Consultant
FluGen Inc.
photo
President, Global Immunization
Sabin Vaccine Institute
photo
Deputy Director, VRC and Chief, Viral Pathogenesis Laboratory and Translational Science Core, NIAID
NIH
photo
CEO
DIOSynVax Ltd.
photo
President & CEO
Human Vaccines Project
photo
Head of North America Commercial Operations
Sanofi Pasteur